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Background: Certain immunoglobulins (Ig) are proposed to have protective functions in atherosclerosis.
Objectives:We testedwhether serum levels of IgG and IgM autoantibodies against malondialdehyde low density
lipoprotein (MDA-LDL) are associated with clinical coronary heart disease (CHD) and unfavorable plaque char-
acteristics.
Methods: NORDIL was a prospective study investigating adverse cardiovascular outcomes in hypertensive
patients. IBIS-3 analyzed lesions in a non-culprit coronary artery with b50% stenosis using radiofrequency intra-
vascular ultrasound (RF-IVUS) and near-infrared spectroscopy (NIRS). Imaging was repeated after a median of
386 days on rosuvastatin. Associations of antibodies with incident CHD and imaging parameters were assessed
in the two sub-studies respectively.
Findings: From 10,881 NORDIL patients, 87 had serum sampled at baseline and developed CHD over 4.5 years,
matched to 227 controls. Higher titers of IgM anti-MDA-LDL had a protective effect on adverse outcomes, with
odds ratio 0.29 (0.11, 0.76; p = 0.012; p = 0.016 for trend). Therefore, the effect was explored at the lesional
level in IBIS-3. 143 patients had blood samples and RF-IVUS measurements available, and NIRS was performed
in 90 of these. At baseline, IgM anti-MDA-LDL levels had a strong independent inverse relationship with lesional
necrotic core volume (p = 0.027) and percentage of plaque occupied by necrotic core (p = 0.011), as well as
lipid core burden index (p= 0.024) in the worst 4 mm segment.
Interpretation: Our study supports the hypothesis that lower circulating levels of IgM anti-MDA-LDL are associ-
ated with clinical CHD development, and for the ﬁrst time relates these ﬁndings to atherosclerotic plaque char-
acteristics that are linked to vulnerability.
© 2018 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY license
(http://creativecommons.org/licenses/by/4.0/).
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1. Introduction
The immune system exerts both protective and pathogenic effects in
atherosclerosis, with a ﬁne balance between maintaining homeostasis
and over-activation [1, 2]. Immunoglobulins (Ig) and speciﬁc antibodies
are relatively stable and easy to quantify, and as such are widely
employed as biomarkers. In the pursuit of better prognostic indicators
of adverse events due to coronary heart disease (CHD), many groups
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have studied the role of antibodies against oxidation-speciﬁc epitopes on
low density lipoprotein (LDL), such as antibodies reacting with
phosphorylcholine or malondialdehyde (MDA) [3]. IgM antibodies have
mostly been found by in vitro and by preclinical studies to have broadly
atheroprotective functions [2, 4, 5]. Furthermore, clinical cardiovascular
studies have shown higher IgM anti-MDA-LDL levels are associated
with less atherosclerotic burden and better outcomes. In contrast, studies
relating IgG antibodies to CHD have been less conclusive [6–15].
In the quest to link the vulnerable patient to the rupture-prone
plaque, it is now important to identify factors in the circulation that
are related with both incident coronary events and negative character-
istics of coronary plaques beyond just degree of arterial narrowing [16,
17]. Although a large necrotic core (NC), thin ﬁbrous cap and a promi-
nent neovasculature are recognized pathological features of plaques
most likely to rupture in untreated subjects, few studies have related
blood biomarkers to unfavorable plaque characteristics [17–20].
Limited work from randomized control studies as well as cohort
studies suggested a link between IgM antibodies against various modi-
ﬁcations of LDL and protection from incident cardiovascular events [13].
However, this needs further veriﬁcation in a high-risk population for
CHD, without previously diagnosed cardiovascular disease (CVD).
Therefore, we set out to demonstrate this association in a specially-
designed nested case control study of the Nordic Diltiazem (NORDIL)
study [21], focusing on antibodies againstwhat is considered to be a sig-
niﬁcant modiﬁcation of LDL, induced by oxidation, in the form of MDA-
LDL.
We ﬁrst presentﬁndings from theNORDIL study [22] conﬁrming the
link between IgM anti-MDA-LDL antibodies and protection from CHD.
Bearing in mind the unavailability of faithful preclinical models of
plaque instability, a major unanswered question is whether levels of
IgM anti-MDA-LDL and other antibodies relate to vulnerable plaque
characteristics. Using intra-coronary imaging data collected by the Inte-
grated Imaging and Biomarker Study 3 (IBIS-3) [23], we assessed levels
of immunoglobulins and anti-MDA-LDL antibodies in relation to de-
tailed information on plaque morphology obtained by radiofrequency
intravascular ultrasound (RF-IVUS) and near infra-red spectroscopy
(NIRS). We report herein that individuals with low IgM anti-MDA-LDL
antibody levels, and to a lesser extent levels of total serum IgM, are
signiﬁcantly more likely to have plaques exhibiting evidence of
vulnerability.
Our ﬁndings provide substantial support for IgM anti-MDA-LDL
antibodies protecting not only from events in NORDIL but also at the
level of the plaque in IBIS-3.
2. Methods
2.1. Study design
2.1.1. NORDIL sub-study
TheNORDIL studyhas been extensively described [21, 22]. It is a pro-
spective randomized open trial with blinded endpoint evaluation,
designed to assess the effect of diltiazem on cardiovascular outcomes
in hypertensive patients versus diuretics, beta-blockers, or both.We de-
signed a nested case control study from the original trial population,
with details of the case and control selection shown in the Supplemen-
tary Methods Section. 187 CVD cases were identiﬁed, of which 88 were
classiﬁed as coronary heart disease (CHD). Controls were selected from
the study population, entered the study before the case was diagnosed
with CVD, and were free from CVD themselves. Up to three controls
from the same risk-set were matched to each case by age (±1 year),
sex and study entry time (±90 days). In total 185 CVD cases were
matched to 494 controls,whilst 87 CHD caseswerematched to 227 con-
trols (Fig. 1A).
2.1.2. IBIS-3 sub-study
IBIS-3 was a prospective cohort study that was designed to deter-
mine the ability of rosuvastatin to decrease NC volume in coronary ath-
erosclerosis. The study was conducted in the Erasmus MC, Rotterdam,
the Netherlands from 2010 until 2013, and the population has previ-
ously been described in detail [23–25]. The study was approved by the
ethics committee of ErasmusMC and all study subjects gave written in-
formed consent. Patients above 18 years of age undergoing diagnostic
coronary angiography (CAG) or percutaneous coronary intervention
(PCI) for either stable CHD or myocardial infarction (MI) were eligible.
After the standard CAG ± PCI, RF-IVUS and NIRS measurements were
performed in a non-culprit coronary artery with a diameter stenosis
b50%. RF-IVUS andNIRSmeasurementswere performed as per standard
protocol. Plaque burdenwasmeasured with grayscale IVUS, NC volume
by RF-IVUS and the lipid core burden index (LCBI) by NIRS [23]. After a
median of 386 days of high dose rosuvastatin treatment (40 mg daily),
the measurements of the same segment were repeated. Fig. 1B details
the IBIS-3 sub-study patient recruitment.
2.2. Biomarkers
Blood samples were drawn at randomization in NORDIL or prior to
the procedures in IBIS-3, and were stored at−80 °C. After study com-
pletion, samples were transported under controlled conditions to the
Vascular Sciences Section at Imperial College, London, UK.Wemeasured
total serum IgM and IgG and speciﬁc antibodies against MDA-LDL by
ELISA, as previously described [7]. Levels of MDA-LDL (a form of oxi-
dized LDL) were assayed using a capture ELISA, using anti-oxLDLmono-
clonal antibody LO1 [26] for MDA-LDL for capture and goat anti-
Apolipoprotein B (ApoB) (Abcam, UK) for biotinylated polyclonal goat
anti-ApoB (Abcam, UK) for detection. Secondary detection was with
horseradish peroxidase (HRP)-conjugated streptavidin (R&D Systems,
Minneapolis, MN) followed by 3,3′,5,5′-tetramethylbenzidine (TMB)
(Sigma Aldrich, UK). To measure ApoB levels, we used a capture ELISA
with goat-anti ApoB (Abcam, UK) as capture antibody, and detected
Research in Context
Evidence before this study
The role of anti-oxidized LDL antibodies in atherosclerosis has
been extensively studied. IgM antibodies were hypothesized to
be largely protective. There is little data linking antibody levels to
plaque characteristics in patients and basic cross-sectional coro-
nary angiography studies have not been conclusive.
Added value
This study conﬁrms that high levels of IgM antibodies against
oxLDL are protective from coronary heart disease in a nested
case control study within a large RCT. In addition, this study
shows for the ﬁrst time, that high levels of these IgM antibodies,
and to a lesser extent total serum IgM, are associated with coro-
nary plaque characteristics that reﬂect plaque stability (i.e.
smaller NC and less lipid core on NIRS). These novel ﬁndings pos-
tulate a mechanistic explanation of how IgM anti-oxLDL antibod-
ies may exert their protective effects in patients with CHD.
Implications of all the available evidence
By linking low IgM antibody levels to clinical CHD and unfavorable
plaque characteristics, our studymay be useful in designing future
immunotherapies for the ‘vulnerable plaque’ as well as in focusing
patient selection for clinical cardio-protection trials and patient
stratification in the clinic.
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with the biotiynlated goat anti-ApoB and HRP as above. The plates were
read at an optical density of 450 nm using a Synergy HT microplate
reader (BioTek, USA). After subtraction of background, the samples
were corrected to a reference plasmawith a standard curve, and results
were expressed in Units (U), as utilized previously [7]. All serological
measurements were undertaken by staff blinded to patient characteris-
tics. Quality control and coefﬁcient of variance (CoV) calculations were
undertaken and samples retested if they exceeded 5% intra-plate CoV
and 15% inter-plate CoV. The intra-plate and inter-plate coefﬁcients of
variation (CoV) for all antibody assays and assay ranges are displayed
in Supplementary Table 1.
2.3. RF-IVUS imaging and measurements
20-MHz IVUS catheters (Eagle-Eye; Volcano Corporation, San Diego,
CA, USA) were used at a continuous motorized pullback speed of 0.5
mm/s (R-100 pullback device; Volcano Corporation). The IVUS images
were analyzed ofﬂine for plaque burden and NC volume by an indepen-
dent core laboratory (Cardialysis BV, Rotterdam, the Netherlands),
blinded for clinical and biomarker data. The IVUS grayscale and IVUS ra-
diofrequency analyses, also known as IVUS virtual histology (IVUS-VH),
were performed using pcVH 2.1 and qVH (Volcano Corp., SanDiego, CA)
software. The external elastic membrane and luminal borders were
contoured for each frame (median inter-slice distance, 0.40 mm).
Extent and phenotype of the atherosclerotic plaque were assessed.
Plaque volume was deﬁned as the total volume of the external elastic
membrane occupied by atheroma [23]. Plaque burden was deﬁned as
plaque andmedia cross-sectional area divided by external elastic mem-
brane cross-sectional area and is presented as a percentage. Brieﬂy,
frames corresponding to the R wave on the ECG were selected. These
images were analyzed using both grayscale as well as the RF virtual
histology and volumes calculated automatically. Following characteri-
zation of the composition of the atherosclerotic plaque, the percentage
and total volume of the NC were determined [23, 27]. Fig. 2 demon-
strates an example of IVUS-VH measurements at baseline and 1 year.
2.4. NIRS
NIRS was performed with the Infraredx system (Infraredx, Burling-
ton, MA, USA), at a pullback speed of 0.5 mm/s. The NIRS-system used
acquires 1000 measurements per 12.5 mm of coronary artery of 1 to
2 mm2 from a depth of approximately 1 mm2 perpendicular to the
long axis of the catheter [28]. The coronary composition is visualized
in a chemogram in which a lipid core is displayed as yellow. The LCBI
is a score from 0 to 1000 that reﬂects the amount of yellow present on
the chemogram. We assessed the LCBI of the entire region of interest,
and of the 10 mm and 4 mm segments with the highest LCBI [29, 30].
Both the 10 and 4 mm segments that were measured at follow-up
corresponded to the exact segment of artery that had the worst 4 or
10 mmmeasured at baseline.
2.5. Statistical analyses
Continuous variables are presented as mean ± standard deviation
(SD) or median± interquartile range (IQR), depending on the normal-
ity of the distribution. Categorical variables are presented as numbers
and percentages. Analyses were performed with R statistical software
(version 3.3.1, available at: www.r-project.org), SAS V9.4 (SAS Institute,
Cary, NC, USA), or STATA V12 (STATA Corporation, College Station, TX,
USA). Two-tailed p values of b0.05 were considered statistically signiﬁ-
cant. Further details on statistical methodology are provided in the Sup-
plementary Methods.
Fig. 1.NORDIL and IBIS-3 sub-study FlowCharts. Fig. 1A–NORDIL sub-study ﬂowchart. Fig. 1B – IBIS-3 sub-study ﬂowchart. CVD: cardiovascular disease; CHD: coronaryheart disease;MI:
myocardial infarction; IHD: ischemic heart disease; IVUS: intravascular ultrasound; NIRS: near-infrared spectroscopy.
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3. Results
3.1. NORDIL sub-study baseline characteristics
The NORDIL study enrolled 10,881 hypertensive patients, of which
1988 samples were available for analysis. 235 cases with CVD were
identiﬁed, of which 187 had no history of CVD at baseline. 88 cases of
CHD were identiﬁed. In total, after samples with no matched controls
and insufﬁcient sera available were removed, 185 CVD cases were
matched to 494 controls, and 87 CHD cases were matched to 227 con-
trols. Baseline characteristics can be seen in Supplementary Table 2.
Mean age was 60·79 (6.37) versus 61·25 (6.30) years in the cases and
controls respectively (59.3% versus 61.6% male). There were no signiﬁ-
cant differences between the groups, with the exception of smoking
rate (p b 0·0001), HDL-cholesterol (p = 0·04) and diabetes (p =
0·021).
3.2. IgM anti-MDA-LDL antibodies confer protection from clinical CHD in
NORDIL
There was a signiﬁcantly higher median level of IgM anti-MDA-LDL
in the controls (0·85 (0·55, 1·20) units) versus the CVD cases (0·76
(0·54, 1·04) units; p = 0·039) at baseline, whereas no relationship
was demonstratedwith IgG anti-MDA-LDL (p= 0·38) (Supplementary
Table 3).
As CVD may have a heterogeneous causal pathology, we focused on
the relationship of antibodies against MDA-LDL with incident CHD
events. After controlling for variables with signiﬁcant inter-group varia-
tion (smoking status, diabetic status, baseline HDL) and randomized
blood pressure treatments, as well as total IgG and IgM, immunoglobu-
lin levels were log-transformed and divided into tertiles. The highest
tertile of IgM anti-MDA-LDL was found to have a substantial protective
effect on the development of CHD, with odds ratio (OR) 0·29 (0·11,
0·76; p= 0·012; p= 0·016 for trend) (Table 1). No such relationship
was found with IgG anti-MDA-LDL antibodies.
3.3. IBIS-3 sub-study baseline characteristics
Weexamined samples from IBIS-3 to explore the putative protective
effect of IgM anti-MDA-LDL antibodies at the level of the atherosclerotic
plaque. Of the 241 patients eligible to start rosuvastatin treatment, 143
had both blood samples and matching baseline and follow-up RF-IVUS
measurements available (Fig. 1B). The present sub-studywas represen-
tative of theparent IBIS-3 study,withnodifferences in any of the patient
characteristics (Table 2). The mean age of participants was 59·6 (9·0)
years and 84·6% of recruits weremale. The study population had exten-
sive risk factors for CHD, including diabetes (28%), hypertension (89%)
and hypercholesterolemia (90%). 41% were current smokers and 5%
had documented renal failure.
3.4. Baseline IgM anti-MDA-LDL antibodies indicate RF-IVUS-derived ne-
crotic core characteristics
At baseline, IgM anti-MDA-LDL antibody levels had a strong inverse
relationship with lesional NC volume (p= 0·027) and percentage (p
= 0·011) (Table 3). Thus, the NC volume associated with the lowest
quartile of IgM anti-MDA-LDL antibodies was more than twice that as-
sociated with the highest quartile. This relationship survived correction
for age, sex, diabetes, smoking and previous use of statins (Table 3,
Trend Model 1). It also survived correction for both HDL- and LDL-
cholesterol levels (Table 3, trend Model 2). The relationship was how-
ever partially dependent on total serum IgM, as lower IgM levels also
reﬂected an unfavorable NC percentage on RF-IVUS (Table 3, Model
3). However, IgM anti-MDA-LDL antibody levels still predicted NC per-
centage after correction for all variables (Table 3, Model 3). There was
no correlation between IgG antibodies, total serum IgG, HDL-
cholesterol, LDL-cholesterol, ApoB or oxLDLwith any of the imaging pa-
rameters (Table 3 and Supplementary Table 4).
3.5. IgM anti-MDA-LDL antibodies predict lipid core burden index at the 4-
mm maximal segment at baseline
In addition to the inverse relationship with lipid core volume and
percentage measured by RF-IVUS, IgM anti-MDA-LDL antibodies were
also able to predict the LCBI in the worst affected 4 mm section
(maxLCBI4mm) in the non-culprit coronary artery segment using
NIRS. The median maxLCBI4mm NIRS score was 308 (183·8, 355·0)
in the lowest quartile of antibody levels, whilst those with the
highest antibody levels had a much lower score (less than half) of
133·0 (22·5, 303·5), p = 0·024 for trend (Table 4). This relationship
also survived correction for age, sex, diabetes, smoking, and previous
use of statins (Table 4, Model 1) as well as HDL and LDL levels
(Table 4, Model 2). However, whilst total serum IgM was not signif-
icantly related to maxLCBI4mm, adjustment for total serum IgM re-
moved statistical signiﬁcance for the inverse relationship between
maxLCBI4mm and IgM anti-MDA-LDL antibodies (Table 4, Model 3).
There was a similar relationship between IgM anti-MDA-LDL and
the larger LCBI regions of interest however these did not reach statis-
tical signiﬁcance. Neither IgG antibodies, LDL- or HDL-cholesterol,
ApoB or oxLDL predicted any of the NIRS-derived parameters
(Table 4 and Supplementary Table 4).
Fig. 2. An Example of Baseline and One Year Intravascular Measurements in IBIS-3 (central illustration). IVUS and NIRS analyses (QCU-CMS®, LUMC, Leiden, The Netherlands and IVUS-
VH®, Philips Volcano, San Diego, USA, IVUS-NIR, Infraredx®, Burlington, MA, USA) at baseline and at 1 year of the left anterior descending artery of a 51 year old male patient that
underwent angioplasty to of the circumﬂex artery. Panels A and A' show respectively the IVUS grayscale longview of the region of interest (ROI) at baseline and at 1 year follow-up. B
and B′ the graphic representation of lumen-, vessel- and plaque areas at baseline and follow-up. Graphs show that there is some decrease in vessel- and plaque size after 1 year without
change in lumen size. Panels C and C′ showNIRS, registeredwith the ROI at baseline and follow-up. The yellow areas indicate lipid richplaque. The highest LCBI in 4 mm is located between
the lines and shows at follow-up a slight decrease. Panels D, E, D' and E' show the VH-analyses of the ROI at baseline and follow-up, showing a signiﬁcant decrease of necrotic core (in red,
26,7 to 20,1%) after 1 year, mostly in favor ofﬁbrous fatty plaque (in light green)which increased from8,3 to 13,6% of the total plaque volume. (Illustration: JurgenM.R. Ligthart, RT; Karen
Th. Witberg, CCRN).
Table 1
Odds ratios of Coronary Heart Disease per tertile of baseline antibodies from the NORDIL
sub-study.
Parameter Cases/Controls OR (95% CI) P value
Per 1 SD increase in loge IgG 87/227 1.00 (0.74, 1.35) 1.00
Tertiles:
0.51–0.91 30/74 1.00 (Ref)
0.92–1.18 24/81 0.65 (0.33, 1.28) 0.22
1.18–2.53 33/72 0.93 (0.45, 1.92) 0.84
Trend p = 0.82
Per 1 SD increase in loge IgM 87/227 0.70 (0.46, 1.06) 0.09
Tertiles:
0.18–0.62 31/73 1.00 (Ref)
0.62–1.07 35/70 0.90 (0.45, 1.80) 0.76
1.08–3.16 21/84 0.29 (0.11, 0.76) 0.012
Trend p = 0.016
Odds Ratios of Coronary Heart Disease in Relation to Baseline IgG and IgM Anti-MDA-LDL
Antibodies (Per Standard Deviation Increase in Log-transformed Antibodies and in Anti-
bodies Tertiles) from the NORDIL sub-study.
Adjusted for signiﬁcant differences between cases and controls (smoking status, diabetic
status, baseline HDL, randomized blood pressure treatments plus either total IgG or total
IgM. Ig: immunoglobulin; HDL: high-density lipoprotein; MDA-LDL: malondialdehyde-
modiﬁed low density lipoprotein; OR: odds ratios; CI: conﬁdence intervals; SD: standard
deviation.
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3.6. Changes in parameters after treatment with rosuvastatin for one year
A comparison between baseline and follow-up data for RF-IVUS and
biomarker variables is shown in Table 5. As expected, LDL was signiﬁ-
cantly reduced and HDL signiﬁcantly increased by −0·76 mmol/L
(−0·92,−0·59; p b 0·001) and 0·13 mmol/L (0·08, 0·17; p b 0·001)
respectively in patients after one year of rosuvastatin treatment. Despite
this, and as observed in the main IBIS-3 study [23], there was an overall
progression in grayscale IVUS measured plaque volume over the one
year study period, with a mean increase of 4·79 (0·23, 9·34) mm3.
However, as there was no change in the gross NC volume, there was a
decrease in NC percentage of −1·25% (−2·29, −0·21) (Table 5).
There were also no signiﬁcant changes seen in NIRS parameters. Inter-
estingly, mean total IgM dropped over one year by 0·16 g/L (−0·27,
−0·05; p = 0·004). There was a trend towards reduction in the IgM
anti-MDA-LDL antibodies, but this was not statistically signiﬁcant.
Total serum IgG and IgG anti-MDA-MDL antibodies were not affected
over the same time period (Table 5). None of the baseline immunoglob-
ulin, antibody or lipid levels were able to predict imaging changes upon
follow-up (Supplementary Tables 5 and 6).
4. Discussion
Although several studies have reported links between higher serum
IgM anti-oxLDL antibody level and lower incidence of CHD, as yet we
have very little knowledge ofwhether high levels of these antibodies re-
late to different plaque characteristics, orwhether protection is by some
other means. We have provided this link herein, ﬁrst demonstrating
that higher levels of IgM anti-MDA-LDL independently confer protec-
tion from CHD in a well-characterized clinical endpoint-driven popula-
tion, and secondly, connecting low IgM anti-MDA-LDL antibody levels
with unfavorable plaque morphology in a well-characterized intravas-
cular coronary imaging study.
The NORDIL sub-study conﬁrms the protective effect of IgM anti-
MDA-LDL on clinical CHD, which has been recognized previously [6–8,
13, 31]. However, apart from a few studies [7, 8], most of the evidence
is derived from general populations, rather than from clinical endpoint
driven studies in high-risk individuals. As such, the ﬁndings from this
NORDIL sub-study, in a hypertensive population, are very useful.
Moreover, we have demonstrated here for the ﬁrst time, a direct in-
verse association between anti-MDA-LDL antibodies and intravascular
imaging (both IVUS and NIRS)-derived unfavorable coronary plaque
characteristics. Our ability to make this association was heavily depen-
dent on the sophisticated intracoronary imaging techniques used for
plaque characterization. Previouswork using conventional angiography
did not ﬁnd a relationship between anti-oxLDL antibodies and overall
disease burden [8], although there are some studies reporting a link
with degree of angiographic stenosis [32]. In keeping with this, we did
not ﬁnd a relationship between antibody levels and the total plaque
burden measured by grayscale IVUS. Rather, the salient ﬁndings of this
study concern more precise characteristics of plaque vulnerability re-
lated to the lipid core. The prognostic relevance of assessing non-
culprit lesions is strongly supported by recent studies in which larger
lipid rich non-culprit plaques were associated with higher risk of future
cardiovascular events [25, 27, 33].
Ourmost striking signiﬁcant ﬁndingwas that low levels of IgM anti-
MDA-LDL antibodies were associated with greater coronary NC volume
and lipid core burden of theworst affected 4 mm segment. Surprisingly,
the antibodies performed far better than lipids in this respect, as levels
of HDL- and LDL-cholesterol, ApoB andoxLDL did not relate signiﬁcantly
to plaque characteristics. Furthermore, the signiﬁcance of associations
for IgM anti-MDA antibodies was not affected by adjusting the data
for levels of LDL- and HDL-cholesterol.
The inverse baseline association between IgM anti-MDA-LDL an-
tibodies and size of the NC is consistent with these antibodies being
directly involved in modifying plaque biology. However, although
the inverse association between IgM anti-MDA-LDL antibodies and
NC percentage survived adjustment for total serum IgM, other IgM
antibodies are no doubt also involved. Firstly, there was a signiﬁcant
link between total serum IgM and NC percentage. Secondly, adjust-
ment for total serum IgM attenuated the inverse association be-
tween IgM anti-MDA-LDL antibodies and NC volume and LCBI
measured by RF-IVUS and NIRS respectively. Thirdly, in vitro and
preclinical mouse studies indicate a broad role for IgM antibodies
in facilitating safe clearance of debris of various types, including
modiﬁed lipoproteins, apoptotic cells, cholesterol crystals and micro-
particles [3, 34].
In contrast to IgM anti-MDA antibodies and total serum IgM, IgG
anti-MDA-LDL antibodies and total serum IgG did not relate to plaque
characteristics. In previous work we demonstrated a strong inverse re-
lationship of total serum IgG with major adverse coronary outcomes
in the primary prevention hypertensive Anglo Scandinavian Cardiac
Outcomes Trial (ASCOT) population [7]. However, it is notable that the
interquartile range of total serum IgG levels in our IBIS-3 patients
(8.3–13.1 g/L) is within the expected normal laboratory range, corre-
sponding to the highest risk bottom tertile of values in the ASCOT pa-
tients (b13.1 g/L). This indicates that the populations are quite
different, and highlights how distinct ‘at risk’ primary populations
may be from those with established coronary disease. The current ﬁnd-
ings are consistent with a model in which IgM antibodies directly inﬂu-
ence “vulnerable plaque”, whilst IgG provides useful insight into the
Table 2
Baseline characteristics of the IBIS-3 sub-study population.
IBIS-3 core: IBIS-3 sub-study: P Value
(n = 164) markers
(n = 143)
Age (SD) 59.8 (9.0) 59.6 (9.0) 0.44
Gender (% men) 138 (84.1) 121 (84.6) 0.67
BMI* (SD) 28.6 (4.4) 28.8 (4.5) 0.12
Statin use (SD) 156 (95.1) 135 (94.4) 0.60
Cardiovascular risk factor (%)
Diabetes 34 (20.7) 28 (19.6) 0.90
Hypertension 104 (64.2) 89 (62.7) 0.28
Hypercholesterolemia ± 103 (63.6) 90 (63.4) 0.89
Current smoker 46 (28.0) 41 (28.7) 0.64
Family history of CAD± 89 (54.6) 76 (53.5) 0.47
Renal failure 6 (3.7) 5 (3.5) 0.57
History of cardiovascular disease (%)
MI 49 (29.9) 42 (29.4) 0.71
CABG 1 (0.6) 0 (0) 0.13
PCI 59 (36.0) 51 (35.7) 0.83
Stroke 15 (9.1) 14 (9.8) 0.70
Indication for coronary angiography (%)
STEMI 24 (14.7) 21 (14.7) 0.44
NSTE ACS 44 (26.8) 36 (25.2)
Stable angina 96 (58.5) 86 (60.1)
PCI performed (%) 146 (89.0) 128 (89.5) 0.71
Time between procedures
(IQR, days)
386 (372–404) 386 (374–403) 0.72
Last used Rosuvastatin dose
(IQR, mg)
40 (20–40) 40 (20–40) 0.93
IBIS 3 core: patients with completed treatment phase and matching baseline and follow-
up RF-IVUS; IBIS-3 substudy: patients with available blood samples for measuring oxLDL;
*missing in 10 patients (both cohorts); missing in 2 patients and one patient respectively;
±missing in 1 patient (both cohorts); RF-IVUS: radiofrequency intravascular ultrasound;
oxLDL: oxidized low density lipoprotein; BMI: bodymass index; CAD: coronary artery dis-
ease;MI:myocardial infarction; CABG: coronary artery bypass grafting; PCI: percutaneous
coronary intervention; STEMI: ST-elevationmyocardial infarction; NSTE ACS; non-ST-ele-
vation acute coronary syndrome. P values derived from testing the differences between
patients included in sub-cohort (n = 143) and those not included (n = 21), using Chi-
square tests and Fisher's Exact tests for categorical variables and t-tests and Mann–Whit-
ney U tests for normally and non-normally distributed continuous variables respectively.
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“vulnerable patient” by reﬂecting a general systemic role(s). This role
may perhaps be having a positive effect by protecting from systemic in-
fections and infection-related inﬂammatory drive to atherosclerosis and
cardiovascular events [35, 36]. Interestingly, there is also now evidence
that (un)switchedmemory B cells have a protective effect on secondary
cardiovascular events [37].
As was the case in the core IBIS-3 study [23], our sub-study failed to
show retardation of total plaque burden progression over the course of a
year, although there was a signiﬁcant reduction in percentage of NC
within lesions. However, a limitation of the study is that we do not
know how plaques would have progressed in the absence of
rosuvastatin. Moreover, we do not knowwhether low immunoglobulin
or speciﬁc antibody levels would have predicted plaque development
and changes in characteristics of vulnerability without the confounding
inﬂuence of statin treatment. It is interesting that IgM levels dropped
over the course of the year, and whether this can be attributed to statin
treatment or even an effect of aging remains to be determined. One fur-
ther limitation of this study, as well as previous studies in the ﬁeld, is
that the antigen used is laboratory modiﬁed MDA-LDL that will express
other epitopes apart fromMDA-modiﬁed protein. This polyclonal reac-
tivity against a spectrum of modiﬁed LDL, or what is more commonly
known as oxLDL, is challenging to dissect and has always been a
limitation of studies using any form of laboratory-modiﬁed LDL as an
antigen [38].
The clinical translational value of our ﬁndings, linking antibody
levels to both favorable clinical outcomes as well as favorable plaque
characteristics, would be in utilization as part of focused patient selec-
tion strategies in clinical trials for novel agents that target high risk pop-
ulations [39, 40], as well as in exploring avenues for targeted
immunotherapies in atherosclerosis [41, 42].
5. Conclusion
We conﬁrm in our study that IgM anti-MDA-LDL antibodies confer
protection from the development of clinical CHD, demonstrated in a hy-
pertensive population. Importantly, we have shown for the ﬁrst time
that low levels of IgM anti-MDA-LDL antibodies, and to a lesser extent
total serum IgM, predict worse NC and LCBI characteristics assessed di-
rectly by intracoronary imaging. These observations not only provide
much needed clinical support for the protective role of humoral immu-
nity in atherosclerosis proposed by preclinical studies, but also point to
the possible use of low IgM anti-MDA-LDL antibody levels as a surrogate
marker of unfavorable plaque characteristics.
Table 3
Baseline RF-IVUS measurements per quartile of baseline antibodies from IBIS-3 sub-study.
Biomarker Plaque Volume Plaque Burden NC Volume NC Percentage
Median mm3 (IQR) Median % (IQR) Median mm3 (IQR) Median % (IQR)
IgM anti-MDA-LDL antibodies Lowest 235.4 (205.6, 330.3) 44.0 (37.3, 49.3) 25.8 (15.7, 44.0) 21.0 (18.2, 25.5)
Second 202.8 (140.2, 294.8) 41.6 (32.3, 50.0) 22.4 (6.1, 47.2) 21.3 (17.6, 23.9)
Third 212.1 (143.2, 272.7) 38.8 (33.7, 47.2) 18.8 (7.7, 33.7) 19.9 (14.9, 24.0)
Highest 188.8 (150.3, 225.8) 36.7 (31.9, 45.9) 11.5 (5.7, 22.8) 17.6 (12.1, 22.5)
Trend Model 1 p = 0.10 p = 0.14 p = 0.027 p = 0.011
Trend Model 2 p = 0.093 p = 0.15 p = 0.024 p = 0.0074
Trend Model 3 p = 0.13 p = 0.38 p = 0.060 p = 0.044
Total Serum IgM Lowest 235.8 (168.9, 304.4) 41.8 (33.1, 45.3) 21.4 (8.9, 38.7) 19.8 (17.3, 25.1)
Second 206.0 (169.0, 342.2) 45.2 (37.4, 49.0) 23.8 (14.2, 59.0) 21.3 (18.6, 25.0)
Third 189.9 (136, 279.3) 38.2 (32.1, 52.5) 18.7 (6.9, 29.3) 19.7 (13.7, 26.1)
Highest 206.7 (150.7, 246.1) 36.7 (31.5, 45.9) 13.9 (6.5, 23.1) 17.7 (12.5, 22.1)
Trend Model 1 p = 0.56 p = 0.43 p = 0.12 p = 0.0071
Trend Model 2 p = 0.51 p = 0.36 p = 0.10 p = 0.0059
IgG anti-MDA-LDL antibodies Lowest 220.3 (139.5, 328.6) 38.6 (32.7, 47.8) 21.2 (8.4, 44.6) 20.3 (17.5, 27.2)
Second 230.1 (175.2, 293.8) 43.0 (34.0, 48.4) 20.3 (13.3, 33.5) 20.2 (15.0, 23.0)
Third 200.8 (147.5, 239.4) 38.2 (32.8, 45.6) 15.7 (6.5, 26.9) 19.4 (14.2, 23.2)
Highest 212.4 (159.6, 334) 42.9 (33.1, 49.5) 20.2 (7.3, 44.0) 20.3 (14.8, 24.9)
Trend Model 1 p = 0.69 p = 0.62 p = 0.38 p = 0.34
Trend Model 2 p = 0.76 p = 0.52 p = 0.44 p = 0.31
Trend Model 3 p = 0.56 p = 0.70 p = 0.32 p = 0.39
Total Serum IgG Lowest 201.2 (144.3, 265.1) 38.9 (32.8, 47.0) 17.7 (8.4, 27.0) 19.5 (17.0–22.6)
Second 211.6 (145.5, 304.2) 42.1 (32.3, 46.1) 15.2 (7.4, 41.9) 19.8 (14.4, 25.9)
Third 245.9 (170.7, 373.6) 42.8 (34.5, 51.0) 23.1 (11.5, 44.4) 20.9 (16.2, 23.6)
Highest 209.8 (148.0, 301.0) 41.1 (28.0, 47.8) 19.1 (4.6, 38.8) 20.0 (12.7, 25.1)
Trend Model 1 p = 0.69 p = 0.88 p = 0.85 p = 0.77
Trend Model 2 p = 0.69 p = 0.89 p = 0.87 p = 0.76
LDL-Cholesterol Lowest 206.0 (136.3, 290.4) 37.3 (30.0, 46.7) 15.8 (6.5, 33.2) 19.8 (15.0, 22.4)
Second 245.9 (165.4, 327.4) 43.8 (34.3, 48.8) 22.7 (8.9, 57.1) 22.0 (18.2, 26.6)
Third 216.4 (146.6, 299.5) 43.1 (33.6, 48.7) 20.3 (6.5, 36.0) 19.7 (14.8, 24.0)
Highest 200.8 (150.0, 253.4) 40.1 (33.8, 45.3) 15.7 (9.3, 23.0) 18.6 (13.5, 24.0)
Trend Model 1 p = 0.91 p = 0.63 p = 0.68 p = 0.19
HDL-Cholesterol Lowest 210.9 (163.2, 246.6) 41.8 (33.0, 47.9) 19.8 (8.0, 27.4) 19.8 (16.4, 22.5)
Second 212.6 (123.0, 333.3) 41.4 (32.5, 49.2) 15.6 (5.4, 55.1) 19.4 (14.2, 23.2)
Third 204.0 (141.5, 268.3) 37.2 (32.6, 45.0) 16.0 (7.7, 32.1) 22.3 (17.5, 25.6)
Highest 229.3 (168.8, 330.6) 43.1 (35.8, 48.1) 21.7 (10.8, 35.8) 18.9 (14.6, 24.4)
Trend Model 1 p = 0.26 p = 0.74 p = 0.37 p = 0.76
P values based on a linear trend test across the four quartiles of the antibodies in a linear regression model,
Model 1: adjustment for age, sex, diabetes, smoking, and previous use of statins.
Model 2: additional adjustment for LDL and HDL-cholesterol.
Model 3: Model 2 plus adjustments for either total IgG or IgM.
RF-IVUS volumes are standardized for themeasured segment length by dividing volume through segment length and thenmultiplication by themedian segment length. HDLwasmissing
in two cases, therefore, the results of model 2, 3 and the results of HDL itself are based on 141 patients.
Immunoglobulin and speciﬁc antibody percentile levels in Units (U) as measured by ELISA (based on OD450) and (in g/L as interpolated per standard curves for total Ig levels) were: total
IgG: 25th centile 0.97 (8.17 g/L), 50th centile 1.09 (10.71 g/L), 75th centile 1.23(13.08 g/L); Total IgM: 25th centile 0.89 (0.65 g/L), 50th centile 1.21 (1.05 g/L), 75th centile 1.49 (1.49 g/L);
IgG anti-MDA-LDL 25th centile 0.30, 50th centile 0.39, 75th centile 0.55; IgM anti-MDA-LDL 25th centile 0.76, 50th centile 1.18, 75th centile 1.64.mm3: cubicmillimeter; IQR: interquartile
range; NC: necrotic core tissue; Ig: immunoglobulins; MDA-LDL: malondialdehyde-modiﬁed low density lipoprotein; HDL: high-density lipoprotein.
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Table 4
Baseline LCBI measured by NIRS per quartile of baseline antibodies, low density lipoprotein and high density lipoprotein from the IBIS-3 sub-study.
Biomarker LCBI full region of interest LCBI max 10 mm LCBI max 4 mm
Median score (IQR) Median score (IQR) Median score (IQR)
IgM anti-MDA-LDL antibodies Lowest 56.0 (33.5, 70.5) 172.5 (118.2, 234.8) 308.0 (183.8, 355.0)
Second 15.0 (0.25, 49.8) 51.0 (0.5, 156.8) 114.5 (1.5, 264.8)
Third 41.5 (7.8, 70.5) 87.0 (361.0, 207.0) 155.5 (73.3, 301.8)
Highest 22.0 (5.0, 56.0) 86.0 (9.5, 161.5) 133.0 (22.5, 303.5)
Trend Model 1 P = 0.29 P = 0.14 P = 0.024
Trend Model 2 P = 0.29 P = 0.15 P = 0.024
Trend Model 3 P = 0.22 P = 0.25 P = 0.11
Total Serum IgM Lowest 40.0 (21.5, 61.0) 148.0 (59.5, 191.0) 230.0 (132.5, 345.5)
Second 42.5 (9.75, 61.75) 139 (29.0, 209.0) 253.0 (67.0, 337.0)
Third 17.5 (0.0, 66.75) 74.0 (0.0, 160.2) 128.0 (0.0, 306.5)
Highest 29.0 (6.0, 71.5) 103.0 (26.5, 186.0) 165.0 (59.5, 303.5)
Trend Model 1 P = 0.89 P = 0.34 P = 0.12
Trend Model 2 P = 0.89 P = 0.36 P = 0.10
IgG anti-MDA-LDL antibodies Lowest 27.0 (14.5, 61.0) 100.0 (54.8, 194.5) 193.5 (125.5, 338.5)
Second 45.5 (27.5, 71.5) 157.5 (55.5, 207.8) 268.5 (131.2, 331.2)
Third 17.0 (0.0, 60.5) 62.0 (0.0, 145.0) 96.0 (0.0, 229.2)
Highest 41.0 (4.0, 76.5) 118.0 (17.0, 245.5) 165.0 (42.0, 325.5)
Trend Model 1 P = 0.93 P = 0.62 P = 0.29
Trend Model 2 P = 0.94 P = 0.59 P = 0.28
Trend Model 3 P = 0.50 P = 0.30 P = 0.14
Total Serum IgG Lowest 27.0 (11.0–61.5) 65.0 (28.5, 171.5) 143.0 (64.0, 292.5)
Second 33.0 (11.8, 59.8) 129.0 (34.5, 201.2) 217.5 (82.3, 339.5)
Third 25.5 (2.0, 60.3) 83.0 (5.5, 163.5) 166.0 (14.8, 333.5)
Highest 45.0 (12.5, 84.5) 153.5 (76.5, 229.8) 216.5 (109.8, 331.2)
Trend Model 1 P = 0.35 P = 0.55 P = 0.66
Trend Model 2 P = 0.36 P = 0.54 P = 0.68
LDL-Cholesterol Lowest 27.0 (3.5, 64.0) 75.0 (9.0, 187.0) 183.0 (22.5, 284.5)
Second 42.0 (24.0, 61.0) 134.0 (59.0, 225.8) 206.0 (124.8, 348.2)
Third 23.5 (2.0, 68.0) 107.0 (4.0, 204.0) 159.0 (11.0, 319.0)
Highest 42.5 (8.5, 76.5) 119.0 (28.5, 173.8) 193.5 (71.8, 332.0)
Trend Model 1 P = 0.63 P = 0.58 P = 0.88
HDL-Cholesterol Lowest 37.0 (7.5, 66.0) 148.0 (28.0, 195.0) 255.0 (66.0, 336.5)
Second 30.0 (5.3, 46.0) 78.0 (9.3, 133.0) 139.5 (20.8, 251.0)
Third 28.0 (7.5, 69.8) 103.0 (27.0, 234.0) 136.0 (60.0, 342.0)
Highest 34.0 (18.5, 70.3) 150.0 (55.3, 212.8) 237.0 (88.3, 328.8)
Trend Model 1 P = 0.93 P = 0.48 P = 0.97
P values based on a linear trend test across the four quartiles of the antibodies in a linear regression model.
Model 1: adjustment for age, se x, diabetes, smoking, and previous use of statins.
Model 2: additional adjustment for LDL and HDL-cholesterol.
Model 3: model 2 plus either total IgG or IgM.
LCBI: lipid core burden index; IQR: interquartile range; NC: necrotic core tissue; Ig: immunoglobulins; MDA-LDL: Malondialdehyde-modiﬁed low density lipoprotein; HDL: high-density
lipoprotein.
During the analyses of the association between the immunoglobulins with LCBI full region of interest and LCBI worst 10mm, a major outlier with a positive effect on the association was
identiﬁed. To ensure the validity of our results and to prevent violation of the assumption of the linear regression models, this patient was discarded from the analyses.
HDL was missing in two cases, therefore, the results of model 2, 3 and the results of HDL itself are based on 88 patients.
Limits of immunoglobulin and speciﬁc antibody quartiles are as in Table 3.
Table 5
Baseline and follow-up RF-IVUS imaging, NIRS measurements, and immunoglobulin levels from the IBIS-3 sub-study.
Baseline Follow-up Change
Mean (SD) Median (IQR) Mean (SD) Median (IQR) Mean (95% CI) p value
Procedural
Plaque volume, mm3 241.6 (149.8) 203.3 (143.6, 304.4) 246.4 (147.9) 208.6 (146.5, 299.7) 4.79 (0.23, 9.34) 0.040
Plaque Burden, % 40.3 (10.2) 40.5 (32.9, 47.8) 41.3 (9.7) 40.9 (33.5, 49.7) 0.95 (0.35, 1.55) 0.002
NC volume, mm3 28.1 (31.0) 17.2 (7.5, 36.7) 27.1 (30.8) 19.1 (6.2, 32.5) −1.00 (−2.65, 0.64) 0.230
NC percentage, % 20.0 (8.1) 19.9 (15.2, 24.9) 18.9 (7.1) 19.6 (14.8, 23.8) −1.25 (−2.29,−0.21) 0.019
LCBI full ROI 45.0 (51.4) 33.5 (7, 66.5) 46.8 (39.6) 41.5 (10.25, 75) −1.7 (−12.6, 9.1) 0.751
LCBI worst 10 mm 130.0 (121.1) 108 (27, 201) 135.0 (111.3) 126 (47, 198) −5.0 (−26.9, 16.9) 0.652
LCBI worst 4 mm 202.9 (162.2) 182 (63, 332) 214.1 (148.9) 203 (89, 325) −11.2 (−40.2, 17.7) 0.443
Biomarker
IgM anti-MDA-LDL antibodies, Units 1.27 (0.61) 1.18 (0.77, 1.62) 1.22 (0.58) 1.19 (0.80, 1.52) −0.07 (−0.15, 0.01) 0.092
Total IgM, g/L 1.26 (1.03) 1.06 (0.65, 1.58) 1.10 (0.75) 0.93 (0.62, 1.34) −0.16 (−0.27,−0.05) 0.004
IgG anti-MDA-LDL antibodies, Units 0.45 (0.39) 0.39 (0.30, 0.54) 0.47 (0.22) 0.42 (0.30, 0.62) 0.06 (−0.01, 0.14) 0.104
Total IgG, g/L 11.2 (4.7) 10.7 (8.3, 13.1) 10.5 (4.7) 10.1 (7.6, 12.6) −0.66 (−1.57, 0.26) 0.159
LDL-cholesterol, mmol/L 2.51 (0.87) 2.37 (1.92, 3.00) 1.75 (0.72) 1.61 (1.28, 2.02) −0.76 (−0.92,−0.59) b0.001
HDL-cholesterol, mmol/La 1.12 (0.31) 1.08 (0.93, 1.30) 1.25 (0.37) 1.22 (0.99, 1.46) 0.13 (0.08, 0.17) b0.001
P values are based on linearmixedmodels (with patients as random intercept) to test if change is different from 0; Antibodies against MDA-LDL are log-transformedwith base number 2.
SD: standard deviation; IQR: interquartile range; CI: conﬁdence interval; mm3: cubicmillimeter; NC: necrotic core tissue; LCBI: lipid core burden index; ROI: region of interest; Ig: immu-
noglobulins; g/L: grams per liter; MDA-LDL: malondialdehyde-modiﬁed low density lipoprotein; HDL: high-density lipoprotein; mmol/L: millimoles per liter.
a Missing in 2 patients.
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